Company Overview and News
Reaffirms Plans to Commence Testing of Fuel in a U.S. Research Reactor By 2020 and Deploy Lead Test Rod in a U.S. Commercial Reactor By 2021
RESTON, Va. , June 27, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel developer, today announced that Jonathan Baggett, Vice President of Program Management and Deputy Nuclear Quality Assurance Manager, will participate in a panel discussion entitled “Suppliers Perspective” at 1:15 PM, ET on Thursday, June 28 at The James Martin Center for Nonproliferation Studies, in Washington, DC.
RESTON, Va., June 19, 2018 (GLOBE NEWSWIRE) -- Executives from Enfission, LLC, a joint venture between Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel developer, and Framatome, a global leader in nuclear fuel, components, and reactor services, will present its cutting-edge metallic fuel technology at a workshop during the World Nuclear Exhibition on June 28 at 12:00 p.m. local Paris time. At the workshop, Enfission CEO Seth Grae and Enfission Project Director Aaron Totemeier will provide an overview of the development of the Lightbridge Fuel technology, designed to make existing and new nuclear power plants significantly more efficient and cost competitive.
RESTON, Va., June 18, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ:LTBR), a U.S. nuclear fuel development company, today announced that it has appointed James D. Fornof, PE, CFA, as Vice President for Government Program Management. In this new role, Mr. Fornof will provide leadership, management and oversight of projects involving government funding, as well as assist the company with implementation of corporate goals and strategic initiatives.
RESTON, Va., May 21, 2018 (GLOBE NEWSWIRE) -- Enfission CEO Seth Grae will provide an update at the Nuclear Energy Institute's annual conference May 22 on the development of the company's metallic fuel technology designed to make both existing and new nuclear power plants more efficient and economical. Enfission is a joint venture of Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel developer, and Framatome, a global supplier of nuclear fuel, plants and services.
MHVYF LTBR 7011
NEW YORK, May 16, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ:LTBR), a U.S. nuclear fuel development company, today announced that it will be presenting at the 19th Annual B. Riley Institutional Investor Conference on Thursday, May 24, 2018 at 2:30 PM, PST. The conference is being held May 23-24, 2018 at the Loews Santa Monica Beach Hotel in Santa Monica, California. Seth Grae, President and CEO of Lightbridge, will be presenting and providing recent business highlights at the event, as well as meeting with investors.
Greetings and welcome to the Lightbridge 2018 First Quarter Earnings and Business Update Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder this conference is being recorded.
RESTON, Va., May 10, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDQ:LTBR), a nuclear fuel technology company, today announced that Seth Grae, CEO of Lightbridge, is scheduled to appear on Varney & Co. on the Fox Business Network at 11:50 AM Eastern this morning to discuss the benefits of the Company’s advanced metallic nuclear fuel.
ltbr_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ltbr_10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
RESTON, Va., May 09, 2018 (GLOBE NEWSWIRE) -- Enfission LLC, a joint venture of Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel technology company, and Framatome, a leader in nuclear fuel, components and reactor services, today announced its board of directors and management team. The companies officially formed Enfission in January to develop, license and sell nuclear fuel assemblies for both existing and new reactors.
MHVYF LTBR 7011
RESTON, Va., May 09, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel technology development company, today announced that it will host a conference call on Thursday, May 10th at 11:00 a.m. Eastern Time to discuss the company's financial results for the first quarter ending March 31, 2018, as well as the Company's corporate progress and other meaningful developments.
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ:LTBR), a U.S. nuclear fuel development company, today announced that it will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference in New York City on Wednesday, May 9th at 12:50 PM, Eastern Time. President and Chief Executive Office of Lightbridge, Seth Grae, will be presenting, as well as meeting with investors.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to LTBR / Lightbridge Corp. on message board site Silicon Investor.
|What is Thorium|
as of ET